1-3 of 3
E. Gabriela Chiorean
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I, Pharmacogenomic, Drug Interaction Study of Sorafenib and Bevacizumab in Combination with Paclitaxel in Patients with Advanced Refractory Solid Tumors

Available to Purchase
E. Gabriela Chiorean, Susan M. Perkins, R. Matthew Strother, Anne Younger, Jennifer M. Funke, Safi G. Shahda, Noah M. Hahn, Kumar Sandrasegaran, David R. Jones, Todd C. Skaar, Bryan P. Schneider, Christopher J. Sweeney, Daniela E. Matei
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2020) 19 (10): 2155–2162.
https://doi.org/10.1158/1535-7163.MCT-20-0277
Published: 02 October 2020
View article titled, Phase I, Pharmacogenomic, Drug Interaction Study of Sorafenib and Bevacizumab in Combination with Paclitaxel in Patients with Advanced Refractory Solid Tumors
Open the PDF for Phase I, Pharmacogenomic, Drug Interaction Study of Sorafenib and Bevacizumab in Combination with Paclitaxel in Patients with Advanced Refractory Solid Tumors in another window
Journal Articles

Abstract A2: Exploratory textural CT evaluation of the combination of TRC105 (anti-endoglin monoclonal antibody; MAb) and bevacizumab (BEV) indicates partial response by Choi criteria in BEV refractory advanced cancer patients (pts) and identifies candidate markers of response.

Free
Ron L. Korn, Michael S. Gordon, Lee S. Rosen, Francisco Robert, Daniela Matei, Jonathan W. Goldman, David S. Mendelson, E. Gabriela Chiorean, Robert Matthew Strother, Ben K. Seon, Delia Alvarez, Bonne J. Adams, Charles P. Theuer
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A2.
https://doi.org/10.1158/1535-7163.TARG-13-A2
Published: 01 November 2013
View article titled, Abstract A2: Exploratory textural CT evaluation of the combination of TRC105 (anti-endoglin monoclonal antibody; MAb) and bevacizumab (BEV) indicates partial response by Choi criteria in BEV refractory advanced cancer patients (pts) and identifies candidate markers of response.
Journal Articles

Combining Hedgehog Signaling Inhibition with Focal Irradiation on Reduction of Pancreatic Cancer Metastasis

Free
Dongsheng Gu, Hailan Liu, Gloria H. Su, Xiaoli Zhang, Helen Chin-Sinex, Helmut Hanenberg, Marc S. Mendonca, Harlan E. Shannon, E. Gabriela Chiorean, Jingwu Xie
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (6): 1038–1048.
https://doi.org/10.1158/1535-7163.MCT-12-1030
Published: 09 June 2013
View article titled, Combining Hedgehog Signaling Inhibition with Focal Irradiation on Reduction of Pancreatic Cancer Metastasis
Open the PDF for Combining Hedgehog Signaling Inhibition with Focal Irradiation on Reduction of Pancreatic Cancer Metastasis in another window
Includes: Supplementary data